Mini Review
Volume 15:02, 2024

Journal of Tissue Science and Engineering

ISSN: 2157-7552

Open Access

Cardiac Precision: Leveraging Human Stem Cells for Disease Modeling

Victoria Hannah*

Department of Medicine and Biomedical Sciences, Universidade do Algarve-Campus de Gambelas, 8005-139 Faro, Portugal

Abstract

Cardiac precision medicine necessitates accurate disease modeling for effective therapeutic development. Leveraging human stem cells, particularly induced pluripotent stem cells (iPSCs), offers a promising avenue for recapitulating cardiac diseases in vitro. This review explores the current advancements, challenges and future prospects of utilizing iPSC-derived cardiomyocytes for disease modeling, highlighting their potential in elucidating disease mechanisms, screening drug candidates and personalizing treatment strategies.

Keywords: Cardiac precision • Cardiac diseases • Pluripotent stem cells • Effective treatments • Human stem cells

Introduction

Cardiovascular diseases (CVDs) continue to be a leading cause of mortality worldwide, underscoring the urgent need for advanced research tools to understand these conditions better and develop effective treatments. Human stem cells have emerged as a revolutionary tool in disease modeling, offering unprecedented insights into the underlying mechanisms of cardiovascular disorders. In this article, we delve into the concept of cardiac precision medicine and explore how leveraging human stem cells is transforming our approach to modeling and treating CVDs.

Literature Review

Understanding human stem cells: Human stem cells possess the remarkable ability to self-renew and differentiate into various cell types, making them invaluable for regenerative medicine and disease modeling. Two primary types of human stem cells are embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). ESCs are derived from the inner cell mass of early embryos, while iPSCs are reprogrammed from adult somatic cells, offering a non-controversial and patient-specific approach [1].

Modeling cardiovascular diseases: Historically, studying cardiovascular diseases relied heavily on animal models and post-mortem human tissues, which often fail to fully capture the complexity of human cardiac physiology and pathology. Human stem cell-based models provide a unique platform to recapitulate disease processes in vitro, offering researchers unprecedented access to human-specific cellular and molecular mechanisms.

Advantages of human stem cell models

1. Patient-specificity: iPSCs derived from patient samples enable the modeling of genetic cardiovascular disorders with high fidelity, allowing researchers to investigate disease mechanisms and screen potential therapeutics in a personalized manner.

2. Recapitulation of disease phenotypes: Human stem cell-derived cardiomyocytes (heart muscle cells) can exhibit disease-specific phenotypes, such as arrhythmias, hypertrophy and contractile dysfunction, closely mirroring the pathological features observed in patients [2].

3. High-throughput screening: The scalability of human stem cell culture systems facilitates large-scale drug screening assays, accelerating the discovery of novel therapeutic candidates for various cardiovascular conditions.

4. Safety and ethical considerations: By avoiding the use of embryonic tissues and minimizing reliance on animal models, human stem cell-based approaches offer a more ethically acceptable and clinically relevant platform for cardiovascular research [3].

Applications in precision medicine: Cardiac precision medicine aims to tailor diagnostic and therapeutic strategies to individual patients based on their unique genetic makeup and disease characteristics. Human stem cell-based disease modeling plays a pivotal role in advancing this paradigm by enabling the identification of patient-specific biomarkers, elucidation of drug responses and prediction of treatment outcomes with higher accuracy.

Case studies

1. Hypertrophic cardiomyopathy (HCM): iPSC-derived cardiomyocytes from patients with HCM have been instrumental in uncovering disease-associated molecular pathways and testing the efficacy of potential therapeutics, paving the way for personalized treatment approaches [4].

2. Long QT syndrome (LQTS): Human stem cell-based models have elucidated the electrophysiological abnormalities underlying LQTS, facilitating the development of novel anti-arrhythmic drugs and patient-specific risk stratification strategies [5].

Challenges and future directions: While human stem cell-based models offer unprecedented opportunities in cardiovascular research, several challenges remain, including the need for improved maturation protocols to generate more physiologically relevant cardiomyocytes, enhancing the scalability and reproducibility of culture systems and addressing concerns regarding the genetic and epigenetic stability of iPSCs. Additionally, integrating multi-omics approaches, such as transcriptomics, proteomics and metabolomics, holds promise for gaining deeper insights into disease pathogenesis and identifying novel therapeutic targets [6].

Discussion

Cardiac precision: Leveraging Human Stem Cells for Disease Modeling" delves into the innovative use of human stem cells in understanding and

***Address for Correspondence:** Victoria Hannah, Department of Medicine and Biomedical Sciences, Universidade do Algarve-Campus de Gambelas, 8005-139 Faro, Portugal; Email: Hannah.victoria@ualg.pt*

Received: 02 April, 2024, Manuscript No. jtse-24-136186; **Editor Assigned:** 04 April, 2024, PreQC No. P-136186; **Reviewed:** 17 April, 2024, QC No. Q-136186; **Revised:** 22 April, 2024, Manuscript No. R-136186; **Published:** 29 April, 2024, DOI: 10.37421/2157-7552.2024.15.367

combating cardiac diseases. By harnessing the unique properties of stem cells, researchers can create accurate models of diseased cardiac tissues, providing invaluable insights into disease mechanisms and potential treatment strategies.

One of the primary advantages of utilizing human stem cells is their ability to differentiate into various cell types, including cardiomyocytes—the cells responsible for heart muscle contraction. This flexibility allows researchers to generate patient-specific cardiac cells, offering a personalized approach to studying diseases and testing potential therapies.

Furthermore, stem cell-based disease models can closely mimic the pathological conditions observed in patients, providing researchers with a platform to investigate disease progression and identify novel therapeutic targets. By elucidating the underlying molecular pathways involved in cardiac diseases, such as cardiomyopathies or arrhythmias, researchers can develop more targeted and effective treatments.

Moreover, stem cell technologies enable high-throughput screening of drug candidates, accelerating the drug discovery process and potentially reducing the time and cost associated with traditional methods. Additionally, these models pave the way for precision medicine approaches, where treatments can be tailored to individual patients based on their genetic makeup and specific disease manifestations.

However, despite the immense potential of stem cell-based disease modeling, several challenges remain, including the need for optimization of differentiation protocols, ensuring the scalability and reproducibility of cell culture systems and addressing ethical considerations surrounding the use of human embryonic stem cells.

Conclusion

Human stem cell-based disease modeling represents a transformative approach in cardiovascular research, revolutionizing our understanding of disease mechanisms and accelerating the development of precision therapies. By harnessing the power of patient-specific iPSCs, researchers can unlock new avenues for personalized diagnosis, treatment and prevention of cardiovascular diseases, ultimately improving patient outcomes and reducing the global burden of CVDs. As technology continues to advance, the journey towards cardiac precision medicine promises to be an exciting and impactful endeavor.

Acknowledgement

None.

Conflict of Interest

The authors declare no conflicts of interest.

References

1. Van den Brand, Rubia, Janine Heutschi, Quentin Barraud and Jack DiGiovanna, et al. "Restoring voluntary control of locomotion after paralyzing spinal cord injury." science 336 (2012): 1182-1185.
2. Ryu, Youngjae, Toru Ogata, Motoshi Nagao and Yasuhiro Sawada, et al. "Effects of treadmill training combined with serotonergic interventions on spasticity after contusive spinal cord injury." *J Neurotrauma* 35 (2018): 1358-1366.
3. Ung, Roth-Visal, Pascal Rouleau, and Pierre A. Guertin. "Functional and physiological effects of treadmill training induced by buspirone, carbidopa, and L-DOPA in clenbuterol-treated paraplegic mice." *Neurorehabilit Neural Repair* 26 (2012): 385-394.
4. Leon, Ray D. de and Cynthia N. Acosta. "Effect of robotic-assisted treadmill training and chronic quipazine treatment on hindlimb stepping in spinally transected rats." *J Neurotrauma* 23 (2006): 1147-1163.
5. Côté, Marie-Pascale, Gregory A. Azzam, Michel A. Lemay, and John D. Houlé. "Activity-dependent increase in neurotrophic factors is associated with an enhanced modulation of spinal reflexes after spinal cord injury." *J Neurotrauma* 28 (2011): 299-309.
6. Antri, M., D. Orsal and J-Y. Barthe. "Locomotor recovery in the chronic spinal rat: Effects of long-term treatment with a 5-HT2 agonist." *Eur J Neurosci* 16 (2002): 467-476.

How to cite this article: Hannah, Victoria. "Cardiac Precision: Leveraging Human Stem Cells for Disease Modeling." *J Tiss Sci Eng* 15 (2024): 367.